Clinical Trial Update: Antioxidant and Immunomodulator Properties of Viusid in Patients With Chronic Hepatitis C [Phase 3]

View source ↗

Summary

The completed Phase 3 trial evaluated Viusid, an antioxidant and immunomodulator, in patients with chronic hepatitis C.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Viusid

Snippet

Sponsor: Catalysis SL | Conditions: Chronic Hepatitis C | Phase 3 | Status: COMPLETED